Starpharma Holdings Current Ratio 2011-2021 | SPHRY

Starpharma Holdings current ratio from 2011 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Starpharma Holdings Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-12-31 $0.05B $0.01B 7.01
2021-06-30 $0.05B $0.01B 6.78
2020-12-31 $0.06B $0.01B 10.30
2020-06-30 $0.03B $0.00B 5.48
2019-12-31 $0.03B $0.01B 6.05
2019-06-30 $0.03B $0.01B 7.44
2018-06-30 $0.05B $0.00B 11.14
2017-12-31 $0.05B $0.00B 12.32
2017-06-30 $0.05B $0.00B 11.90
2016-12-31 $0.03B $0.00B 7.31
2016-06-30 $0.04B $0.01B 5.25
2015-06-30 $0.03B $0.01B 5.19
2014-12-31 $0.04B $0.00B 10.26
2014-06-30 $0.03B $0.00B 7.46
2013-12-31 $0.03B $0.00B 11.17
2013-06-30 $0.04B $0.00B 16.03
2012-12-31 $0.04B $0.00B 14.04
2012-06-30 $0.05B $0.01B 8.26
2011-12-31 $0.05B $0.00B 21.62
2011-06-30 $0.02B $0.00B 9.81
2010-12-31 $0.02B $0.00B 10.01
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.157B $0.002B
Starpharma Holdings Limited is engaged in the development of dendrimer products for pharmaceutical, life science and other applications. The Company's primary product in development is VivaGel, a microbicide gel for women used for the prevention and treatment of bacterial vaginosis and a range of sexually transmitted diseases. It also develops dendrimers as specialty chemicals for industrial applications. Starpharma Holdings Limited is headquartered in Melbourne, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $152.052B 9.22
GSK (GSK) United Kingdom $62.454B 7.50
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
QIAGEN (QGEN) Netherlands $9.939B 16.64
Ginkgo Bioworks Holdings (DNA) United States $6.283B 0.00
Myovant Sciences (MYOV) United Kingdom $2.444B 0.00
Arcus Biosciences (RCUS) United States $1.941B 37.89
Emergent Biosolutions (EBS) United States $1.068B 6.19
ADC Therapeutics SA (ADCT) Switzerland $0.402B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Enzo Biochem (ENZ) United States $0.113B 0.00
Gelesis Holdings (GLS) United States $0.083B 0.00
SQZ Biotechnologies (SQZ) United States $0.073B 0.00
Ambrx Biopharma (AMAM) United States $0.042B 0.00
Biohaven Pharmaceutical Holding (BHVN) United States $0.000B 0.00